Skip to main content
VXRT
OTC Life Sciences

Vaxart's Oral COVID-19 Vaccine Shows Positive 12-Month Safety in Phase 2b Sentinel Cohort

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.584
Mkt Cap
$149.342M
52W Low
$0.261
52W High
$0.845
52W Position info
124% above low
Off High info
31% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

VXRT has more than doubled off its 52-week low of $0.261 on light trading volume (0.4× avg).

Summary

Vaxart reported positive 12-month safety data from the sentinel cohort of its Phase 2b oral COVID-19 vaccine trial, with no serious adverse events, supporting continued development.


Key Events · Product Development and Regulatory · VXRT

  • Positive Phase 2b Safety Data

    The oral pill COVID-19 vaccine candidate showed no vaccine-related serious adverse events (SAEs) or sustained Grade 3 or higher adverse events over 12 months in the 400-participant sentinel safety cohort.

  • Favorable Adverse Event Profile

    Common adverse events for the oral vaccine were generally less severe and frequent than those reported for the mRNA vaccine comparator, particularly regarding injection site reactions.

  • Full Efficacy Data Expected in 2027

    This sentinel cohort was not powered for efficacy. Topline data from the complete 5,400-participant study, including efficacy, is anticipated in 2027.

  • BARDA Funding Continues

    The vaccine development is supported by a Project NextGen award from BARDA, valued at up to $344.8 million, which this positive safety data helps to underpin.


Analysis · VXRT · Life Sciences

Vaxart announced encouraging 12-month safety data from the initial 400-participant sentinel cohort of its Phase 2b oral COVID-19 vaccine trial. The absence of vaccine-related serious adverse events or sustained severe adverse events is a critical positive step for the program, especially as the company continues to develop its oral vaccine platform with significant BARDA funding. While this data does not include efficacy, it de-risks the safety profile ahead of the full study readout in 2027.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VXRT was trading at $0.58 on OTC in the Life Sciences sector, with a market capitalization of approximately $149.3M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VXRT - Latest Insights

VXRT
Nov 05, 2026, 4:26 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.365
Real-time Price: $0.3677 info
Change: +$0.0027 (+0.74%) info
Market Cap: $89.609M info
VXRT
Nov 05, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.365
Real-time Price: $0.3677 info
Change: +$0.0027 (+0.74%) info
Market Cap: $89.609M info
VXRT
Nov 05, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.365
Real-time Price: $0.3677 info
Change: +$0.0027 (+0.74%) info
Market Cap: $89.609M info
VXRT
Jul 17, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.515
Real-time Price: $0.3677 info
Change: -$0.1473 (-29%) info
Market Cap: $89.609M info
VXRT
Jul 06, 2026, 6:09 AM EDT
Filing Type: DEFA14A
Importance Score:
8
Price at Filing: $0.584
Real-time Price: $0.3677 info
Change: -$0.2163 (-37%) info
Market Cap: $89.609M info